• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Halt Medical lands FDA nod for game-changing uterine fibroid treatment

Halt Medical lands FDA nod for game-changing uterine fibroid treatment

November 6, 2012 By MassDevice staff

Halt Medical logo

Women’s health devices maker Halt Medical announced a U.S. regulatory win for its game-changing uterine fibroid treatment, providing an alternative for women who refuse hysterectomy.

"Acessa is the 1st product cleared anywhere in the world that can be used by gynecologists to treat all fibroid symptoms and types," Halt CEO Jeffrey Cohen said in prepared remarks.

The technology represents a major shift in treatment of uterine fibroids, the company noted. Fibroids are the leading global cause of hysterectomy procedures, according to the Centers for Disease Control & Prevention.

 "It’s estimated that 97% of women with fibroids choose to suffer with their symptoms rather than having their uterus removed.  We’re about to change all that," Cohen added. "Finally, gynecologists will have an alternative to hysterectomy for their fibroid patients."

The Las Vegas, Nev.-based company’s Acessa system, which is already on the market in Canada and Europe, allows physicians to deliver radiofrequency energy to uterine fibroids through a minimally invasive procedure.

In traditional fibroid surgery a physician generally must either cut through healthy tissue to access the tumor or remove the uterus entirely, according to Halt Medical.

A patient treated with Acessa can typically leave the hospital the same day resume regular activities in 5 days or less, according to a press release. The destroyed fibroid is re-absorbed by surrounding tissue.

The company has been expanding ts San Francisco manufacturing efforts in order to prepare to meet new demand, according to a press release.

Filed Under: Food & Drug Administration (FDA), News Well, Women's Health Tagged With: Halt Medical

More recent news

  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy